Cannabinoids for Chronic Pain
Two attendance options:
DMU faculty, staff, students, residents, and the medical community.
- List the three FDA-approved cannabinoid-based medications.
- Determine when cannabinoids might be considered for a patient with chronic pain.
- Weigh the risks and benefits of cannabinoid therapy.
- Identify Iowa guidelines and regulations pertaining to the use of cannabinoid therapy.
Jolene Smith, DO, DABA, DABA-PM
Pain Medicine Physician, Pain Specialists of Iowa
Karry Smith, PhD, MPH
Founder and Medical Writer, Periphas Science Group
Relevant to the content of this educational activity, Dr. Karry Smith indicated she is a consultant for MedPharm Iowa and Dr. Jolene Smith indicated she is a consultant for Boston Scientific.
The Health Effects of Medical marijuana and Cannabinoids: The Current State of Evidence and Recommendations for Research (2017), published by the National Academies of Sciences, Engineering, and Medicine, presents nearly 100 conclusions related to the health effects of medical marijuana and cannabinoids use. In addition to the full report, you can download a PDF of a summary of the committee’s conclusions; there are also links to other resources on report webpage.
FDA and Marijuana webpage, US Food and Drug Administration, provides an overview and links to related information including FAQs and warning letters.
Medical marijuana webpage, National Center for Complementary and Integrative Health, National Institutes of Health, provides an overview and links to resources for patients and clinicians.
Marijuana webpage, National Institute on Drug Abuse, National Institutes of Health, provides information on health effects of marijuana and links to resources.
AOA recommends reclassification of cannabis. The AOA supports reclassification of cannabis as a Schedule II Drug to facilitate advancement in clinical, public health, patient safety and health policy research.
“Enforcing Federal Drug Laws in States Where Medical Marijuana Is Lawful,” by Lawrence O. Gostin, JD; James G. Hodge Jr., JD, LLM; and Sarah A. Wetter, JD, published in JAMA, April 10, 2018, describes the 2018 rescission of federal limits on enforcement of medical marijuana and discusses its possible consequences on state laws and clinicians. (Subscription or purchase required.)
“Cannabinoids for Medical Use: A Systematic Review and Meta-analysis,” by Penny F. Whiting, PhD;, Robert F. Wolff, MD; Sohan Deshpande, MSc; et al, published in JAMA, June 23/30, 2015, is a systematic review of the benefits and adverse events of cannabinoids from 28 databases.
The Role of the Physician in "Medical" Marijuana, a position paper published April 12, 2010, by the President’s Action Committee on Medical Marijuana of the American Society of Addiction Medicine, describes a series of findings, conclusions, and recommendations regarding the therapeutic value of smoked marijuana and the role of physicians in prescribing of marijuana for medical purposes.
“Americans' View of Marijuana is Rosy, and Unscientific,” by Linda Carroll, published in Reuters, July 23, 2018, describes the results of a survey of US adults that looked at public opinions of marijuana and how Americans perceive the impacts of its use.
Des Moines University is located on a 22-acre campus in the heart of Des Moines, Iowa. Just west of downtown on Grand Avenue, the University is located in one of Des Moines' most prestigious neighborhoods. The campus is in a historic neighborhood filled with tree-lined streets and gracious older homes and businesses. Its central location makes it easy to access the rest of the city and outlying communities. The campus is close to the Des Moines International Airport, located on the bus line and just blocks from local shopping and downtown Des Moines.
Continuing Education Credit
- MD: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS). Des Moines University (DMU) is accredited by the IMS to provide continuing medical education for physicians. DMU designates this live activity for 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- DO: Des Moines University (DMU) is accredited by the American Osteopathic Association (AOA) to provide osteopathic continuing medical education for physicians. DMU designates this program for a maximum of 1.0 AOA Category 1-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
- Nurse: Des Moines University is Iowa Board of Nursing approved provider #112. This live activity has been reviewed and approved for 1.0 continuing education contact hour(s). No partial credit awarded.
- Other healthcare providers: This live activity is designated for 1.0 AMA PRA Category 1 Credit(s)™.
No commercial interest company provided financial support for this continuing education activity.
Everyone in a position to control the content of this educational activity will disclose to the CME provider and to attendees all relevant financial relationships with any commercial interest. They will also disclose if any pharmaceuticals or medical procedures and devices discussed are investigational or unapproved for use by the U.S. Food and Drug Administration (FDA). Determination of educational content and the selection of speakers is the responsibility of the activity director. Firms providing financial support did not have input in these areas. The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The content of each presentation does not necessarily reflect the views of Des Moines University.
- 1.00 AOA Category 1A
- 1.00 AMA PRA Category 1 Credits™
- 1.00 IBON
- 1.00 CE Contact Hour(s)